Breakthrough combination therapy tackles drug resistance in lung cancer with common KRAS mutation
Peer-Reviewed Publication
Updates every hour. Last Updated: 25-May-2025 00:09 ET (25-May-2025 04:09 GMT/UTC)
A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib—an FDA-approved drug in the market—and an experimental drug called FGTI-2734, which could make precision medicine more effective for patients with a highly resistant form of lung cancer. The study, featured on the cover of the Journal of Thoracic Oncology, reveals a potential game-changer for patients battling tumors with the KRAS G12C mutation—a driver in about 14% of non-small cell lung cancers.
Scientists discovered genes in the tuberculosis bacterium that becomes essential for the pathogen’s survival when it’s exposed to air through coughing. These genes could be targets for new therapies that simultaneously treat infection and prevent transmission.
A team of NYU scientists has developed an AI model that can identify aspects of human behavior in videoconferences, such as conversational turn-taking and facial actions, and predict, in real-time, whether or not the meetings are seen as enjoyable and fluid—comfortable and flowing rather than awkward and marked by stilted turn-taking—based on these behaviors.